Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)– #Bctn–Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CID-078, a first-and-only-in-class cyclin A/B RxL inhibitor. This milestone marks a significant advancement in the development of novel drug candidates generated by Circle’s proprietary MXMO™ platform for difficult-to-drug targets in oncology and othe
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks